European Penny Stocks To Watch: NX Filtration And Two Others

The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index experiencing a decline amid rising oil prices and geopolitical tensions. Despite these headwinds, investors continue to explore opportunities in various segments of the market, including penny stocks. Though often considered outdated, penny stocks remain a relevant investment area for those seeking potential value in smaller or newer companies. With solid financial foundations, these stocks can offer surprising stability and growth potential.

Let's dive into some prime choices out of the screener.

NX Filtration (ENXTAM:NXFIL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: NX Filtration N.V. develops, produces, and sells hollow fiber membrane modules across the Netherlands, Europe, North America, Asia, and internationally with a market cap of €185.81 million.

Operations: The company's revenue is derived from two main segments: Clean Municipal Water, contributing €5.14 million, and Sustainable Industrial Water, generating €8.55 million.

Market Cap: €185.81M

NX Filtration N.V., with a market cap of €185.81 million, operates in the water filtration sector, deriving revenue from Clean Municipal Water (€5.14 million) and Sustainable Industrial Water (€8.55 million). Despite reporting a net loss of €12.35 million for the half year ending June 2026, its revenue increased to €7.81 million from €6.56 million year-over-year. The company remains unprofitable with less than one year of cash runway based on current free cash flow but benefits from a stable weekly volatility (5%) and satisfactory net debt to equity ratio (7.8%). Management is experienced with an average tenure of 2.2 years, and no meaningful shareholder dilution occurred recently.

• Click to explore a detailed breakdown of our findings in NX Filtration's financial health report.
• Gain insights into NX Filtration's future direction by reviewing our growth report.

Siili Solutions Oyj (HLSE:SIILI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Siili Solutions Oyj is a company that specializes in AI-powered software development, operating both in Finland and internationally, with a market capitalization of €21.24 million.

Operations: The company's revenue segment is primarily derived from Information Systems Development Services, totaling €100.59 million.

Market Cap: €21.24M

Siili Solutions Oyj, with a market cap of €21.24 million, faces challenges as its recent half-year results show sales declining to €50.06 million from €57.54 million year-over-year, alongside a net loss of €2.44 million compared to previous income. The company is unprofitable and has experienced increased losses over the past five years at 28.6% annually. Despite trading at good value relative to peers and reducing its debt-to-equity ratio significantly over time, Siili's high volatility and inexperienced management team contribute to uncertainty in its financial outlook amidst lowered revenue guidance for 2026 due to market conditions.

• Jump into the full analysis health report here for a deeper understanding of Siili Solutions Oyj.
• Assess Siili Solutions Oyj's future earnings estimates with our detailed growth reports.

Molecular Partners (SWX:MOLN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Molecular Partners AG is a clinical-stage biotechnology company focused on designing and developing ankyrin repeat protein therapeutics for oncology treatments in Switzerland, with a market cap of CHF120.28 million.

Operations: Molecular Partners AG has not reported any revenue segments.

Market Cap: CHF120.28M

Molecular Partners AG, with a market cap of CHF120.28 million, is a pre-revenue biotechnology firm focused on oncology treatments. The company recently announced MP0730 as its lead Radio-DARPin candidate targeting CD70, with promising preclinical data presented at a Boston conference. Despite being unprofitable and not expected to achieve profitability in the next three years, Molecular Partners has no debt and maintains sufficient cash runway for over a year based on current free cash flow. While its share price is highly volatile, the management team and board are experienced, providing some stability amidst financial challenges.

• Dive into the specifics of Molecular Partners here with our thorough balance sheet health report.
• Explore Molecular Partners' analyst forecasts in our growth report.

Summing It All Up

• Jump into our full catalog of 300 European Penny Stocks here.
• Looking For Alternative Opportunities? AI is about to change healthcare. These 124 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com